These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7684320)

  • 1. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
    Berg SL; Savarese DM; Balis FM; Denicoff AM; Hillig M; O'Shaughnessy JA; Poplack DG; Cowan KH
    Cancer Res; 1993 Jun; 53(11):2587-90. PubMed ID: 7684320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
    Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor.
    Savarese DM; Denicoff AM; Berg SL; Hillig M; Baker SP; O'Shaughnessy JA; Chow C; Otterson GA; Balis FM; Poplack DG
    J Clin Oncol; 1993 Sep; 11(9):1795-803. PubMed ID: 7689093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
    Erlichman C; Moore M; Kerr IG; Wong B; Eisenhauer E; Zee B; Whitfield LR
    Cancer Res; 1991 Dec; 51(23 Pt 1):6317-22. PubMed ID: 1933893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination pathways of [14C]losoxantrone in four cancer patients.
    Joshi AS; Pieniaszek HJ; Vokes EE; Vogelzang NJ; Davidson AF; Richards LE; Chai MF; Finizio M; Ratain MJ
    Drug Metab Dispos; 2001 Feb; 29(2):96-9. PubMed ID: 11159796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
    Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH
    Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey.
    Berg SL; Balis FM; Godwin KS; Poplack DG
    Invest New Drugs; 1993 Nov; 11(4):255-61. PubMed ID: 8157468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).
    Ames MM; Loprinzi CL; Collins JM; van Haelst-Pisani C; Richardson RL; Rubin J; Moertel CG
    Cancer Res; 1990 Jul; 50(13):3905-9. PubMed ID: 2191768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of pyrazoloacridine in the rhesus monkey.
    Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
    Cancer Res; 1991 Oct; 51(20):5467-70. PubMed ID: 1913666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
    Goldberg RM; Reid JM; Ames MM; Sloan JA; Rubin J; Erlichman C; Kuffel MJ; Fitch TR
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2363-70. PubMed ID: 9815635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
    Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
    Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
    Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
    Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
    Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.